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Objective: This study aims to investigate whether single-nucleotide polymorphisms (SNPs) CYP2C9 and
VKORC1 can be used to adjust effective warfarin treatment for aboriginal Taiwanese population.
Materials and Methods: This study investigates the association of SNPs CYP2C9 and VKORC1 and clinical
factors [sex, age, and body mass index (BMI)] with variable responses to warfarin treatment in 42
aboriginal and 63 Han Taiwanese people.
Results: The incidence of the VKORC1-1639AA genotype and the effective warfarin dosage were similar in
the populations studied. However, the required dosage of warfarin for women with VKORC1-1639AA
polymorphism was signiﬁcantly lower than for their male counterparts.
Conclusion: This result provides guidance for prescribing an effective warfarin dosage for aboriginal and
Han Taiwanese patients with genetic polymorphisms.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Warfarin is the most common oral anticoagulant for patients
with cardioembolic stroke and for secondary prevention of venous
thromboembolism, acute myocardial infarction, embolic stroke,
and chronic atrial ﬁbrillation [1e3]. However, the dosage required
for a therapeutic effect varies widely among different people and
ethnic groups [4e7]. The therapeutic dosage range of warfarin is
narrow, and there is a risk of serious bleeding with overdosing [8].
Complex factors including age, body mass index (BMI), sex, intake
of vitamin K, concomitant diseases, and drugs inﬂuence the
effective warfarin dosage [8e10]. In addition to the potential in-
ﬂuence of these clinical variables, inherited differences in drug
metabolism and drug targets can also affect the efﬁcacy and
toxicity of warfarin.
Twenty-nine genes are suspected to mediate the effects of
warfarin, mainly contributing to the pharmacokinetics and phar-
macodynamics of the drug [11]. Most pharmacogenomic research
on warfarin has been based on association studies examining
polymorphisms in the cytochrome p450 2C9 (CYP2C9) and vitaminiology and Human Genetics,
Road, Hualien, Taiwan. Tel./
ddhist Compassion Relief Tzu ChiK epoxide reductase complex 1 (VKORC1) genes. Common variants
in the CYP2C9 and VKORC1 genes, combined with a subset of
environmental determinants, account for approximately 50e60% of
the variability in the required warfarin dosage [11,12].
The CYP2C9 gene, which encodes for the key enzyme that me-
tabolizes warfarin, has a number of functional variants associated
with lower warfarin requirements. For example, CYP2C9*2 and
CYP2C9*3 differ in prevalence among different ethnic groups [13e
16]. However, these two CYP2C9 genetic polymorphisms cannot
account for lower warfarin requirements among Chinese patients
because they rarely occur in Asian populations [17e19]. Mutation in
the coding region of the VKORC1 gene has been shown to cause
multiple coagulation factor deﬁciency type 2 and warfarin resis-
tance [20,21]. Several single-nucleotide polymorphisms (SNPs) of
the VKORC1 gene also correlate with variable warfarin dosages and
adverse bleeding events [22,23]. Yuan et al reported that the
VKORC1 promoter polymorphism (-1639G>A) was present in all
warfarin-sensitive patients. They showed that the frequency of the
AA genotype was signiﬁcantly higher in Han Chinese than in a
Caucasian population receiving warfarin. Later, several other
studies also demonstrated that the VKORC1 promoter poly-
morphism (-1639G>A) is a major determinant of warfarin response
in anticoagulated patients of various ethnic groups [18,24e28].
The Taiwanese population is comprised of 98% Han Chinese
and 2% aboriginal. The Han Chinese people have been immigrating
to Taiwan since the 17th century, whereas aborigines have beenFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Primers used for ampliﬁcation and sequencing of polymorphisms of the CYP2C9 and
VKORC1 genes.
Gene Forward primer Reverse primer
CYP2C9*3 50-CCCCTGAATTGCT
ACAACAAA-30
50-GGGACTTCGAAAA
CATGGAG-30
VKLRC1
(1639G>A)
50-CAGAAGGGTAGG
TGCAACAGTAA-30
50-CACTGCAACTTGTT
TCTCTTTCC-30
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linguistic backgrounds of Taiwanese aborigines differ from Han
Chinese people, but are closely related to other Austronesian
ethnic groups found across the islands of Southeast Asia [29].
Warfarin is not widely considered in treating Taiwanese aborigines
because the effective dosage range and pharmacogenomic asso-
ciations have not been investigated; therefore, the risk of adverse
bleeding is high. Elucidating the association of CYP2C9 and
VKORC1 SNPs with the effective warfarin dosage for Taiwanese
aborigines will ensure precise prescription and treatment. This
study investigates the frequency of CYP2C9 and VKORC1 SNPs in
aboriginal and Han Taiwanese patients and analyzes the associa-
tion of these SNPs with warfarin responses and adverse bleeding
effects at different dosages. Our results demonstrated that the
effective warfarin dosage ranges and incidence of the VKORC1-
1639 variant are similar for the two populations studied. More
than 80% of recruited patients carried the VKORC1-1639AA geno-
type, which is associated with a lower warfarin maintenance
dosage. The CYP2C9*3 allele, which contributes to warfarin-
sensitive responses in the Caucasian population, was not found
among the recruited patients. Among VKORC1-1639AA carriers, the
required warfarin dosage for women was signiﬁcantly lower than
for men. Our results can provide guidance for clinicians in pre-
scribing an effective warfarin dosage to aboriginal Taiwanese and
genetically related Austronesians.
2. Materials and methods
2.1. Ethics statement
This research was approved by the Institutional Review Board of
Buddhist Tzu Chi Medical Center (IRB096-58). All patients who
participated in this study provided written informed consent
before blood sampling for genetic analysis as well as for publication
of the clinical data.
2.2. Recruited patients
From 2006 to 2009, researchers recruited patients receiving
maintenance warfarin therapy for secondary stroke prevention
who had a stable international normalized ratio (INR) between 1.5
and 3 for 3 months. Anticoagulation of all patients was stably
controlled with a target INR between 1.5 and 3, according to
different indications, for the prevention of secondary stroke [2,30].
Indicators for warfarin treatment included different stroke
subtypes including cardioembolic infarction, embolic infarction of
unknown origin, basilar artery occlusion with brain-stem infarc-
tion, and stroke in evolution. The stroke subtype of the recruited
patients was diagnosed and clariﬁed by magnetic resonance im-
aging of the brain. Cardioembolic stroke was veriﬁed by examining
the thrombus in the left atrium of the heart through a trans-
esophageal endoscopic examination. Stroke in evolution was
deﬁned clinically as neurological deﬁcit progression within 48
hours after a stroke.
Concomitant liver function tests, including evaluating levels of
aspartate transaminase (AST) and alanine transaminase (ALT) [31],
were done, and patients with moderate to severe liver function
impairment were excluded. A questionnaire based on principles of
reference [32] was completed by recruited patients or their fam-
ilies; patients with poor compliance to warfarin therapy were also
excluded based on the answers provided by the patients on the
questionnaire. The ethnicity of patients was included in the ques-
tionnaire. A participant was considered Han Taiwanese or aborig-
inal Taiwanese if his or her parents were both of that same ethnic
group.Clinical data collection consisted of a review of inpatient and
outpatient medical records. Retrospectively, researchers collected
clinical factors such as age, sex, body weight, height, concurrent
medications, and concomitant diseases, which could inﬂuence the
response to warfarin. The average warfarin maintenance dosage
was the mean dosage between two consecutive INR values
collected from the medical records. Any adverse bleeding events
during anticoagulation were recorded in the medical records.
Venous blood was sampled from participants for genomic DNA
extraction and genetic analysis.
2.3. Genomic DNA extraction
Approximately 10 mL of venous blood was drawn from each
patient using ethylenediaminetetraacetic acid (EDTA) tubes and
sent to a laboratory for genomic DNA extraction. Leukocyte DNA
was isolated using a commercial DNA puriﬁcation kit (QIAamp DNA
Mini Kit; QIAGEN, Hamburg, Germany) from 10mL of venous blood,
according to the manufacturer’s instructions. After puriﬁcation,
genomic DNA integrity was veriﬁed through electrophoresis on 1%
TriseacetateeEDTA agarose gel. The concentration of genomic DNA
was measured spectrophotometrically at 260 nm.
2.4. DNA sequencing
DNA sequences of CYP2C9 and VKORC1 were analyzed according
to the National Center for Biotechnology Information database.
Primerswere used to detect CYP2C9*3 allelic variants in exon 7 of the
CYP2C9geneand-1639G>Avariants in theVKORC1promoter regions
as listed in Table 1. Primers were designed using the primer 3 poly-
merase chain reaction primer program. Genotypes of CYP2C9*3 and
VKORC1-1639G>A were extracted using the direct DNA-sequencing
method (3700 DNA analyzer; Applied Biosystems, Grand Island,
NY) at the National Yang-Ming University Genome Research Center.
Sequence variants were directly analyzed by DNA sequence viewer
software (Chromas Lite v2.01). This research did not generate new
gene-sequencing data.
2.5. Statistical analysis
The warfarin maintenance dose was compared across VKORC1-
1639 genotypes and ethnic groups using Student unpaired t test.
The Chi-square test was used to analyze sex across the VKORC1
genotype. A simple regression test correlated the warfarin dose
with variables including age, sex, and BMI. The results are reported
as mean  standard deviation. A p value < 0.05 was considered to
be signiﬁcant.
3. Results
3.1. Patient characteristics
The frequencies of CYP2C9*3 and VKORC1-1639G>A sequence
variants were analyzed in 105 stroke patients regularly receiving
warfarin with stable INR monitoring for 3 months. The mean age of
these patients was 65.6  2.2 years (range: 46e84 years). The sex
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BMI was 25.8  2.7 (range: 20.6e30.1). Liver function tests,
including measurement of AST and ALT levels, were within the
normal ranges (mean AST: 27.9  2.5 IU/L, range: 12e66 IU/L; and
mean ALT: 22.8  2.7 IU/L, range: 8e77 IU/L) in all patients but one
who had mildly elevated liver function results. Recruited patients
were 60% (n ¼ 63) Han and 40% (n ¼ 42) aboriginal Taiwanese
(Table 2). All participants in this study met strict recruiting criteria,
and all aborigine patients had a pure genetic background. Ethnicity
was determined after the patients signed informed consents. Par-
ticipants were required to have parents who were both Han
Taiwanese or both aboriginal Taiwanese to be eligible for this study.
The medical indicators for warfarin therapy were cardioembolic
stroke (83.8%), basilar artery occlusion with brain-stem infarction
(11.4%), and stroke in evolution (4.8%). The average stable target INR
in the recruited patients was 2.19  0.05 (range: 1.60e2.69) and
was calculated according to standard guidelines [2,3,30,33]. The
average maintenance dosage of warfarin was the mean dosage
during the period when two consecutive INR values were collected
from the medical records. The mean daily maintenance dose of
warfarinwas 3.15 0.3 mg (range: 1e6mg) to achieve an INR value
2.19  0.05 (range: 1.60e2.69).
Researchers also recorded and analyzed concomitant chronic
illnesses and concurrent administration of drugs in recruited pa-
tients, which could inﬂuence the warfarin maintenance dosage
[9,34]. There was an average of 2.5  0.2 concomitant chronic
disorders per patient (range: 1e4 disorders). The most common
concomitant disorders were hypertension (63.8%), hyperlipidemia
(56.2%), chronic atrial ﬁbrillation (9.5%), diabetes mellitus (11.4%),
and coronary artery disease (12.4%), which are all risk factors for
cerebrovascular disorders. The mean number of concurrent medi-
cations taken by the recruited patients was 3.4  0.3 (range: 1e6).Table 2
Demographic data of recruited patients.
Characteristic Patients (n ¼ 105)
Age [y; mean (range)] 65.6 (46e84)
Sex (n, %)
Male n ¼ 74, 70.5%
Female n ¼ 31, 29.5%
BMI [mean  SD (range)] 25.8  2.7 (20.6e30.1)
Liver function test
AST [IU/L; mean  SD (range)] 27.9  2.5 (12e66)
ALT [IU/L; mean  SD (range)] 22.8  2.7 (8e77)
Concomitant diseases [type, IU/L; mean  SD
(range)]
2.5  0.2 (1e4)
Hypertension (n, %) n ¼ 67, 63.8%
Hyperlipidemia (n, %) n ¼ 59, 56.2%
Atrial ﬁbrillation (n, %) n ¼ 10, 9.5%
Diabetes mellitus (n, %) n ¼ 12, 11.4%
Coronary artery diseases (n, %) n ¼ 13, 12.4%
Concurrent medications [no.; mean n  SD (range)] 3.4  0.3 (1e6)
Indication for warfarin (n, %)
Cardioembolic stroke n ¼ 88, 83.8%
BAO with brain-stem infarction n ¼ 12, 11.4%
Stroke in evolution n ¼ 5, 4.8 %
INR [mean n  SD (range)] 2.19  0.05 (1.60e2.69)
Warfarin dosage [mg/day; mean n  SD (range)] 3.1  0.3 (1e6)
Ethnic group (n, %)
Han Taiwanese n ¼ 63, 60%
Aboriginal Taiwanese n ¼ 42, 40%
CYP2C9 genotype (n, %)
*1/*1 105, 100%
VKORC1 genotype (n, %)
AA 89, 84.8%
AG 16, 15.2%
GG 0
ALT ¼ alanine transaminase; AST ¼ aspartate transaminase; BAO ¼ basilar artery
occlusion; BMI ¼ body mass index; INR ¼ international normalized ratio;
SD ¼ standard deviation; y ¼ years.Interactions with concurrent medications with warfarin were
analyzed according to a review lecture by Holbrook et al, and
included atorvastatin (n ¼ 13), phenytoin (n ¼ 5), omeprazole
(n ¼ 7), diltiazem (n ¼ 6), allopurinol (n ¼ 5), fenoﬁbrate (n ¼ 1),
and nonsteroidal anti-inﬂammatory drugs (n ¼ 3) [9].
3.2. Required warfarin dosage for Han and aboriginal Taiwanese
patients is similar
The mean daily warfarin dose required to maintain a stable INR
between 1.60 and 2.69 among patients was 3.15  0.3 mg (range:
1e6 mg). Student unpaired t test showed that the mean warfarin
dosage was similar for Han and aboriginal Taiwanese patients
(3.0  0.4 mg/day for Hans and 3.3  0.4 mg/day for aborigines,
p ¼ 0.51) to achieve a stable INR.
3.3. Frequency of CYP2C9 and VKORC1-1639G>A variants in
warfarin-treated Han and aboriginal Taiwanese patients is similar
The CYP2C9*3 and VKORC1-1639G>A SNPs were selected for
analysis because these two genetic polymorphisms have been re-
ported to be themain contributors to variablewarfarin responses in
different populations [25,27]. All Taiwanese Han and aboriginal
patients treated with warfarin carried the CYP2C9*1 variant; no
CYP2C9*3 variant was recorded. The VKORC1-1639AA genotype was
found in the majority of patients (89/105, 84.8%). Among them,
82.5% (52/63) of Han and 88% (37/42) of aboriginal Taiwanese pa-
tients were carriers (Table 3). The remaining patients had the
VKORC1-1639AG genotype (17.5% for Han Taiwanese and 12% for
aboriginal Taiwanese patients). The VKORC1-1639GG genotype was
not detected.
3.4. Association analysis of the VKORC1-1639G>A genotype with
warfarin dosage
To evaluate the association of the VKORC1 genotype with the
daily warfarin dosage, the mean warfarin dosages were analyzed
and compared against different VKORC1 genotypes using Student
unpaired t test. Patients with VKORC1-1639AA had signiﬁcantly
lower dosage requirements (mean: 2.51  0.2 mg/day; range: 1e
5 mg/day, p < 0.001) than those with the heterozygous VKORC1-
1639AG genotype (mean: 4.28  0.2 mg/day, range: 4e6 mg/day)
(Table 3). The mean required warfarin dosage was similar for both
Han (2.33mg/day) and aboriginal Taiwanese patients (3.19mg/day)
with the AA genotype (p ¼ 0.08).
3.5. Association of age, sex, and BMI with effective warfarin dosage
Consistent with the results of previous studies, data from this
study showed that the warfarin dosage requirement correlated
negatively with age, decreasing by 1.1mg per decadewithin the ageTable 3
Clinical characteristics of patients against the VKORC1 genotype.
Clinical characteristic 1639AA
(n ¼ 89)
1639AG
(n ¼ 16)
p
Men:women (n) n ¼ 58:31 n ¼ 16:0 d
Hans:aborigines n ¼ 52:37 n ¼ 11:5 d
Mean age  SD (y) 66  2.3 65  6.2 0.72
Mean BMI  SD (y) 25  2.3 24  0.8 0.31
Mean maintenance INR  SD (y) 2.18  0.05 2.18  0.21 0.29
Required dosage of warfarin (mg/day) 2.51  0.2 4.28  0.2 0.0009
BMI ¼ body mass index, calculated as body weight (kg)/body height (m2);
INR ¼ international normalized ratio ¼ (patient prothrombin time/mean normal
prothrombin time)ISI; SD ¼ standard deviation; y ¼ years.
Fig. 2. Correlation of sex with warfarin dosage requirement. The histogram shows the
mean warfarin dosage by sex. Student unpaired t test was used to compare the mean
warfarin dosage used in men and women with the same genotype (VKORC1-1639AA).
The difference had no relation to age or body mass index. *: p < 0.05.
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differences (Fig. 1). To examine the correlation between sex and
warfarin dosage, the dosage was compared between men and
women with the same VKORC1-1639AA genotype. The warfarin
dosage required to achieve an INR between 1.60 and 2.69 (p< 0.01)
in women was signiﬁcantly lower (n ¼ 31, 1.96 mg/day) than that
required to achieve the same INR in men (n ¼ 58, 3.07 mg/day)
(Fig. 2). This difference had no relation to age and could not be
explained by differences in the BMI between men and women
(p ¼ 0.51). No woman had the VKORC1-1639AG genotype among
our recruited patients.
4. Discussion
This study demonstrated that the frequency of the CYP2C9 and
VKORC1-1639G>A polymorphisms in aboriginal Taiwanese patients
is similar to those in Han Taiwanese patients, and veriﬁed that
VKORC1-1639AA can also indicate a need for a lower warfarin
maintenance dosage to prevent secondary stroke in Taiwanese
aborigines. The warfarin maintenance dosage was negatively
correlated with age. In addition, researchers discovered that the
maintenance dosage was lower for women than men carrying the
same VOKRC-1639AA polymorphism.
Consistent with previous studies for the Asian populations [16],
the CYP2C9*3 polymorphismwas not present in the Han Taiwanese
patients recruited for this study. The data also demonstrated that
the aboriginal Taiwanese people, who have a different genetic
background from Hans, do not carry this polymorphism either. All
patients had the CYP2C9*1 wild-type genotype. Thus, the CYP2C9
genetic polymorphism cannot explain variable warfarin responses
observed in the Taiwanese population.
The majority of patients, both in the Han (82.5%) and in the
aboriginal (88%) population, had the VKORC1-1639AA genotype. No
signiﬁcant difference in the frequency of VKORC1-1639AA was
observed between the two populations studied. Patients with the
VKORC1-1639AA genotype required a signiﬁcantly lower daily
warfarin dose (2.51  0.2 mg/day) than patients with the VKORC1-
1639AG genotype (4.28  0.2 mg/day, p < 0.001). The mean
warfarin dosage requirement was similar between Han
(2.33  0.6 mg/day) and aboriginal Taiwanese patients
(3.19  1.2 mg/day) who had the same VKORC1-1639AA genotype
(p ¼ 0.08). The differences in warfarin sensitivity between patients
with the VKORC1-1639AA and AG genotypes could be explained by
changes in VKORC1 promoter activity. Yuan et al demonstrated thatFig. 1. Correlation of age with warfarin dosage. The correlation between age and
warfarin dosage is analyzed using simple linear regression analysis. The regression line
represents the regression equation y ¼ 0.1136x þ 10.404, R2 ¼ 0.6149. Dosage re-
quirements for warfarin fall with age, decreasing by approximately 1.1 mg per decade
between the age of 45 years and 85 years, irrespective of genotype, body weight,
ethnic group, or sex.VKORC1 promoter activity is decreased by the VKORC1-1639AA
polymorphism. Decreased levels of VKORC1 messenger RNA can
lead to lower VKORC1 activity, and ultimately result in a lower
required warfarin dosage for appropriate anticoagulation [35].
Previous studies have shown that the warfarin dosage require-
ment diminishes with age. Older patients show increased sensi-
tivity to the anticoagulant effects of this drug [36]. The cause of this
phenomenon is unknown, and may be due to a combination of
pharmacokinetic and pharmacodynamic factors. This study also
found that the warfarin dosage requirement was reduced by
approximately 1.1 mg per decade within the age range of 45e85
years. This ﬁnding conﬁrms those of previous studies and suggests
that physicians prescribe a lower warfarin dosage for elderly
Taiwanese patients because of a higher risk of bleeding [10,34,36].
Whether sex is a factor contributing to variability in patient
responses to warfarin remains controversial. Regardless of genetic
polymorphisms, some previous studies reported no gender differ-
ences for the warfarin dosage in atrial ﬁbrillation patients [37] and
Han Chinese patients [38], whereas others indicated that women
were more sensitive to warfarin than men [39e41]. This study
found signiﬁcantly different warfarin dosage requirements be-
tween men (3.07 mg/day) and women (1.96 mg/day, p < 0.01) with
the same VKORC1-1639AA genotype. The gender difference for
VKORC1-1639AA carriers could not be explained by differences in
BMI (p ¼ 0.51). Several factors have been studied to explain gender
differences in the pharmacokinetics of drugs, including the rate of
gastric emptying, intestinal transit time, expression of gut enzymes,
total body water space, muscle mass, organ blood ﬂow, organ
function, body fat, and hepatic metabolism [42]. Further research is
necessary to elucidate the cause of gender differences in the
warfarin dosage for the VKORC1-1639AA population.
Two patients demonstrated adverse bleeding during the course
of warfarin therapy, although they had stable INR monitoring. One
patient presented with upper gastrointestinal bleeding, and the
other demonstrated spontaneous retroperitoneal hematoma.
Warfarin treatment was withdrawn from these two patients
immediately when bleeding was noted. Two other patients showed
variable warfarin responses (INR between 1.12 and 4.02) with a
steady warfarin maintenance dosage (approximately 1.5e1.75 mg/
day). However, no hemorrhage was detected, even in patients with
unstable INRs. These four patients had the VKORC1-1639AA geno-
type; therefore, other genetic factors in addition to VKORC1-1639AA
polymorphism may contribute to the variable warfarin responses
observed in these cases.
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the primary polymorphism in the VKORC1 gene contributing to the
need for a reduced warfarin dosage in the Taiwanese population,
including the genetically different aboriginal population. The fre-
quency of the VKORC1-1639G>A genotype is similar between Han
and aboriginal Taiwanese patients, and the VKORC1-1639AA geno-
type correlates strongly with a lower daily warfarin dose in both
Han and aboriginal Taiwanese patients. Women require a lower
warfarin dosage than men in the VKORC1-1639AA genotype group.
Combining genetic information of VKORC1-1639G>A poly-
morphism with the age and sex of patients may enable physicians
to choose an optimal warfarin maintenance dosage for members of
the Taiwanese population. The results will not only beneﬁt Taiwa-
nese aborigines, but will also be valuable for clinicians prescribing
warfarin to other patients with Austronesian genetic backgrounds.Acknowledgments
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